{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894241817216.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1089/mab.2017.0050"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/full-xml/10.1089/mab.2017.0050"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1089/mab.2017.0050"}}],"dc:title":[{"@value":"Establishment of H\n                    <sub>2</sub>\n                    Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n                    Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast cancer and is associated with poor clinical outcomes. In addition, HER2 expression has been reported in other cancers, such as gastric, colorectal, lung, and pancreatic cancers. An anti-HER2 humanized antibody, trastuzumab, leads to significant survival benefits in patients with HER2-overexpressing breast cancers and gastric cancers. Herein, we established a novel anti-HER2 monoclonal antibody (mAb), H\n                    <jats:sub>2</jats:sub>\n                    Mab-119 (IgG\n                    <jats:sub>1</jats:sub>\n                    , kappa), and characterized its efficacy against pancreatic cancers using flow cytometry, Western blot, and immunohistochemical analyses. H\n                    <jats:sub>2</jats:sub>\n                    Mab-119 reacted with pancreatic cancer cell lines, such as KLM-1, Capan-2, and MIA PaCa-2, but did not react with PANC-1 in flow cytometry analysis. Western blot analysis also revealed a moderate signal for KLM-1 and a weak signal for MIA PaCa-2, although H\n                    <jats:sub>2</jats:sub>\n                    Mab-119 reacted strongly with LN229/HER2 cells. Finally, immunohistochemical analyses with H\n                    <jats:sub>2</jats:sub>\n                    Mab-119 revealed sensitive and specific reactions against breast and colon cancers but did not react with pancreatic cancers, indicating that H\n                    <jats:sub>2</jats:sub>\n                    Mab-119 is useful for detecting HER2 overexpression in pancreatic cancers using flow cytometry and Western blot analyses.\n                  </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825894241817216","@type":"Researcher","foaf:name":[{"@value":"Shinji Yamada"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1420285329316871680","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"40878401"},{"@type":"NRID","@value":"1000040878401"},{"@type":"NRID","@value":"9000414924605"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/tgif"}],"foaf:name":[{"@value":"Shunsuke Itai"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"},{"@value":"Tokyo Medical and Dental University"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817218","@type":"Researcher","foaf:name":[{"@value":"Takuro Nakamura"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817345","@type":"Researcher","foaf:name":[{"@value":"Yao-Wen Chang"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817344","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Harada"}],"jpcoar:affiliationName":[{"@value":"Tokyo Medical and Dental University"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817346","@type":"Researcher","foaf:name":[{"@value":"Hiroyoshi Suzuki"}],"jpcoar:affiliationName":[{"@value":"Sendai Medical Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817217","@type":"Researcher","foaf:name":[{"@value":"Mika K. Kaneko"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894241817219","@type":"Researcher","foaf:name":[{"@value":"Yukinari Kato"}],"jpcoar:affiliationName":[{"@value":"Tohoku University Graduate School of Medicine"},{"@value":"Tohoku University"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"21679436"},{"@type":"EISSN","@value":"21679436"}],"prism:publicationName":[{"@value":"Monoclonal Antibodies in Immunodiagnosis & Immunotherapy"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2017-11-27","prism:volume":"36","prism:number":"6","prism:startingPage":"287","prism:endingPage":"290"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/full-xml/10.1089/mab.2017.0050"},{"@id":"https://journals.sagepub.com/doi/pdf/10.1089/mab.2017.0050"}],"createdAt":"2017-11-27","modifiedAt":"2026-03-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360009142539388544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H\n                    <sub>2</sub>\n                    Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279865059968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643782473344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Anti-HER2 Monoclonal Antibody H\n                    <sub>2</sub>\n                    Mab-181 for Gastric Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643782488576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H\n                    <sub>2</sub>\n                    Mab-181) Using Enzyme-Linked Immunosorbent Assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230618181120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340710124800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340713613440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor activities against breast cancers by an afucosylated <scp>anti‐HER2</scp> monoclonal antibody <scp>H<sub>2</sub>Mab‐77‐mG<sub>2a</sub></scp>‐f"}]},{"@id":"https://cir.nii.ac.jp/crid/1361975844243370240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H\n                    <sub>2</sub>\n                    Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1089/mab.2017.0050"},{"@type":"OPENAIRE","@value":"doi_dedup___::1969605f7568bb29975313db44536421"},{"@type":"CROSSREF","@value":"10.1089/mab.2020.0009_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1089/mab.2022.0022_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1089/mab.2021.0021_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1089/mab.2021.0029_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1089/mab.2022.0023_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1016/j.str.2024.02.007_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1111/cas.16008_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"},{"@type":"CROSSREF","@value":"10.1089/mab.2019.0017_references_DOI_JvRe4tcgu9eaBUuraNL1PzVnfXx"}]}